NeuroSpray™: Precision Nose-to-Brain Drug Delivery Platform

Why Reproducibility Matters in CNS Drug Development

Central nervous system (CNS) drug development is accelerating, and delivery strategy is becoming increasingly important to program success. Developers continue to face challenges related to invasiveness, speed of onset, and limited CNS exposure associated with conventional routes of administration. At the same time, demand is growing for non-invasive, self-administered therapies that fit into real-world treatment settings. As a result, greater attention is being placed on delivery platforms that can support both therapeutic objectives and practical usability.

Why Consistency Remains a Critical N2B Challenge: How can developers improve reproducibility in nose-to-brain drug delivery?

One of the key challenges in N2B development is ensuring that administration conditions consistently support delivery to upper-nasal regions associated with the olfactory and trigeminal pathways. Variations in spray angle, insertion depth and user technique can influence deposition outcomes and make clinical results more difficult to interpret. As developers seek greater confidence in CNS programs, interest is growing in delivery systems designed to reduce user-dependent variability and support more reproducible administration conditions. NeuroSpray™ was developed specifically with this objective in mind, combining targeted upper-nasal delivery with reduced technique sensitivity to help support consistent administration across dosing events.

Moving Beyond Conventional Nasal Delivery

Scientific understanding of olfactory and trigeminal transport pathways has evolved significantly in recent years. As a result, nose-to-brain delivery is increasingly viewed as a targeting and reproducibility challenge rather than a general nasal drug delivery discussion. NeuroSpray™ was developed specifically for this context as a multi-dose platform engineered for CNS-focused applications. Rather than serving broad nasal indications, the platform is designed to support more precise engagement of upper-nasal regions associated with nose-to-brain delivery while helping maintain administration consistency across dosing events.

A Performance Objective Built Around Targeting

Aptar Pharma’s NeuroSpray™ is positioned around a clear and measurable objective: maximise olfactory deposition while maintaining performance when administration conditions vary. According to platform performance data, NeuroSpray™ can achieve up to 50% olfactory deposition under varied spray angles, compared with approximately 1–5% for standard pumps. This focus on quantifiable targeting supports a development approach where delivery performance can be measured rather than assumed. The platform is also evaluated through a combination of performance characterization, preclinical assessments, and human-factors studies, reinforcing its development-oriented positioning.

Why Measurable Performance Is Becoming Essential

As CNS development programs become more sophisticated, developers increasingly seek evidence linking device use, deposition behaviour, and clinical outcome interpretation. NeuroSpray™ is aligned with key performance parameters relevant to nose-to-brain development, including spray pattern, droplet size distribution, reliability, and regional deposition. This evidence-driven approach helps improve understanding of how administration conditions may influence delivery outcomes and supports more informed development decisions.

From Device Performance to Development Confidence

How can developers build greater confidence into nose-to-brain development programs? The answer extends beyond device mechanics alone. Developers increasingly seek delivery platforms that combine targeted deposition, reproducible administration, and development support within a single integrated approach. NeuroSpray™ is positioned within Aptar Pharma's broader development ecosystem, bringing together formulation support, usability engineering, performance characterization, and clinical development capabilities. This approach helps align device performance and formulation behaviour early, enabling teams to better understand deposition outcomes, optimize administration conditions, and reduce development risk.

As nose-to-brain delivery continues to evolve, precision and reproducibility remain central priorities. By combining quantified upper-nasal targeting, reduced sensitivity to administration variability, and integrated development support, NeuroSpray™ supports a more evidence-driven approach to CNS delivery. The result is a platform designed to strengthen development confidence while advancing greater consistency and clinical interpretability in nose-to-brain programs.